1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Graves Disease Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Graves Disease Market, by End User
8.1.1. Hospitals
8.1.1.1. Market Revenue and Forecast
8.1.2. Clinics
8.1.2.1. Market Revenue and Forecast
8.1.3. Homecare Settings
8.1.3.1. Market Revenue and Forecast
9.1. Graves Disease Market, by Treatment Type
9.1.1. Antithyroid Medications
9.1.1.1. Market Revenue and Forecast
9.1.2. Radioactive Iodine Therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Surgery
9.1.3.1. Market Revenue and Forecast
10.1. Graves Disease Market, by Diagnosis Method
10.1.1. Blood Test
10.1.1.1. Market Revenue and Forecast
10.1.2. Imaging Techniques
10.1.2.1. Market Revenue and Forecast
10.1.3. Physical Examination
10.1.3.1. Market Revenue and Forecast
11.1. Graves Disease Market, by Phase of Treatment
11.1.1. Initial Diagnosis
11.1.1.1. Market Revenue and Forecast
11.1.2. Maintenance Therapy
11.1.2.1. Market Revenue and Forecast
11.1.3. Post-Treatment Monitoring
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by End User
12.1.2. Market Revenue and Forecast, by Treatment Type
12.1.3. Market Revenue and Forecast, by Diagnosis Method
12.1.4. Market Revenue and Forecast, by Phase of Treatment
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by End User
12.1.5.2. Market Revenue and Forecast, by Treatment Type
12.1.5.3. Market Revenue and Forecast, by Diagnosis Method
12.1.5.4. Market Revenue and Forecast, by Phase of Treatment
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by End User
12.1.6.2. Market Revenue and Forecast, by Treatment Type
12.1.6.3. Market Revenue and Forecast, by Diagnosis Method
12.1.6.4. Market Revenue and Forecast, by Phase of Treatment
12.2. Europe
12.2.1. Market Revenue and Forecast, by End User
12.2.2. Market Revenue and Forecast, by Treatment Type
12.2.3. Market Revenue and Forecast, by Diagnosis Method
12.2.4. Market Revenue and Forecast, by Phase of Treatment
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by End User
12.2.5.2. Market Revenue and Forecast, by Treatment Type
12.2.5.3. Market Revenue and Forecast, by Diagnosis Method
12.2.5.4. Market Revenue and Forecast, by Phase of Treatment
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by End User
12.2.6.2. Market Revenue and Forecast, by Treatment Type
12.2.6.3. Market Revenue and Forecast, by Diagnosis Method
12.2.6.4. Market Revenue and Forecast, by Phase of Treatment
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by End User
12.2.7.2. Market Revenue and Forecast, by Treatment Type
12.2.7.3. Market Revenue and Forecast, by Diagnosis Method
12.2.7.4. Market Revenue and Forecast, by Phase of Treatment
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by End User
12.2.8.2. Market Revenue and Forecast, by Treatment Type
12.2.8.3. Market Revenue and Forecast, by Diagnosis Method
12.2.8.4. Market Revenue and Forecast, by Phase of Treatment
12.3. APAC
12.3.1. Market Revenue and Forecast, by End User
12.3.2. Market Revenue and Forecast, by Treatment Type
12.3.3. Market Revenue and Forecast, by Diagnosis Method
12.3.4. Market Revenue and Forecast, by Phase of Treatment
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by End User
12.3.5.2. Market Revenue and Forecast, by Treatment Type
12.3.5.3. Market Revenue and Forecast, by Diagnosis Method
12.3.5.4. Market Revenue and Forecast, by Phase of Treatment
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by End User
12.3.6.2. Market Revenue and Forecast, by Treatment Type
12.3.6.3. Market Revenue and Forecast, by Diagnosis Method
12.3.6.4. Market Revenue and Forecast, by Phase of Treatment
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by End User
12.3.7.2. Market Revenue and Forecast, by Treatment Type
12.3.7.3. Market Revenue and Forecast, by Diagnosis Method
12.3.7.4. Market Revenue and Forecast, by Phase of Treatment
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by End User
12.3.8.2. Market Revenue and Forecast, by Treatment Type
12.3.8.3. Market Revenue and Forecast, by Diagnosis Method
12.3.8.4. Market Revenue and Forecast, by Phase of Treatment
12.4. MEA
12.4.1. Market Revenue and Forecast, by End User
12.4.2. Market Revenue and Forecast, by Treatment Type
12.4.3. Market Revenue and Forecast, by Diagnosis Method
12.4.4. Market Revenue and Forecast, by Phase of Treatment
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by End User
12.4.5.2. Market Revenue and Forecast, by Treatment Type
12.4.5.3. Market Revenue and Forecast, by Diagnosis Method
12.4.5.4. Market Revenue and Forecast, by Phase of Treatment
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by End User
12.4.6.2. Market Revenue and Forecast, by Treatment Type
12.4.6.3. Market Revenue and Forecast, by Diagnosis Method
12.4.6.4. Market Revenue and Forecast, by Phase of Treatment
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by End User
12.4.7.2. Market Revenue and Forecast, by Treatment Type
12.4.7.3. Market Revenue and Forecast, by Diagnosis Method
12.4.7.4. Market Revenue and Forecast, by Phase of Treatment
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by End User
12.4.8.2. Market Revenue and Forecast, by Treatment Type
12.4.8.3. Market Revenue and Forecast, by Diagnosis Method
12.4.8.4. Market Revenue and Forecast, by Phase of Treatment
12.5. Latin America
12.5.1. Market Revenue and Forecast, by End User
12.5.2. Market Revenue and Forecast, by Treatment Type
12.5.3. Market Revenue and Forecast, by Diagnosis Method
12.5.4. Market Revenue and Forecast, by Phase of Treatment
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by End User
12.5.5.2. Market Revenue and Forecast, by Treatment Type
12.5.5.3. Market Revenue and Forecast, by Diagnosis Method
12.5.5.4. Market Revenue and Forecast, by Phase of Treatment
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by End User
12.5.6.2. Market Revenue and Forecast, by Treatment Type
12.5.6.3. Market Revenue and Forecast, by Diagnosis Method
12.5.6.4. Market Revenue and Forecast, by Phase of Treatment
13.1. Horizon Therapeutics (Amgen Inc.)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. F. Hoffmann-La Roche Ltd
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck KGaA
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Crinetics Pharmaceuticals
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sanofi
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Sun Pharmaceutical Industries Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Thermo Fisher Scientific Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Tourmaline Bio
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Viridian Therapeutics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
